Publications by authors named "David Sallman"

Claim this Profile
C
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study.
Irfan Yasin, Anna Stengel, Haipeng Shao, Amandeep Kaur, Emily F Mason, David A Sallman

Cancer· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.
Swati Naik, Richard Aplenc, Susanne H C Baumeister, Marco Becilli, Anand S Bhagwat, David A Sallman

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings.
Mikkael A Sekeres, Sangeetha Venugopal, Namrata S Chandhok, Justin M Watts, Terrence Bradley, David A Sallman

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.
Daniel Pollyea, Tessa Kerre, Dries Deeren, Yves Beguin, Tara L Lin, David A Sallman

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative assessment of molecular-based prognostic models in CMML.
Luis E Aguirre, Najla Al Ali, Somedeb Ball, Akriti G Jain, David A Sallman

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Outcomes of Patients With Myelodysplastic Syndrome (MDS) by IPSS-R Scores at Academic Cancer Centers.
Connor Willis, Andre Hejazi, Vonetta L Williams, Craig Comperatore, Srinivas Tantravahi, David A Sallman

Adv Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.
David A Sallman, Amy F McLemore, Rami S Komrokji, Hany Elmariah, Andrew T Kuykendall

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims.
Rami S Komrokji, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, David A Sallman

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.
Traci L Kruer, Ariel Quintana, Hannah Newman, Meghan Ferrall-Fairbanks, Ling Zhang, David A Sallman

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia.
Somedeb Ball, Akriti G Jain, Najla Al Ali, Luis E Aguirre, Jan Philipp Bewersdorf, David A Sallman

Am J Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell spatial mapping reveals dynamic bone marrow microarchitectural alterations and enhances clinical diagnostics in MDS.
Ryan Nachman, Aleksandra Kopacz, Caitlin Unkenholz, Jian Chai, Arvin Ruiz, David Sallman

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression.
Luis E Aguirre, Somedeb Ball, Akriti Jain, Najla Al Ali, David A Sallman

Clin Lymphoma Myeloma Leuk· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.
Amy E DeZern, Sylvain Thepot, Stephane de Botton, Andrea Patriarca, Dries Deeren, David A Sallman

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.
Clifford M Csizmar, Anuya Natu, Mark Gurney, Saubia Fathima, Ali Khalid A Alsugair, David Sallman

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Karyotypic clonal fraction predicts adverse outcome in -mutated myeloid neoplasms: an International investigators Network (iTiN) study.
Madhavi Pandiri, Anna Stengel, Jingjing Zhang, Peng Wang, Haipeng Shao, David Sallman

J Clin Pathol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
Joshua F Zeidner, David A Sallman, Christian Récher, Naval G Daver, Anskar Y H Leung

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival.
Rami S Komrokji, Muhammad Ammad-Ud-Din, Najla H Al Ali, Zhuoer Xie, Onyee Chan, David A Sallman

Clin Lymphoma Myeloma Leuk· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can we harmonize classification of TP53 mutant MDS/AML?
David A Sallman

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with mutant MDS/AML.
David A Sallman, Rami S Komrokji, Amy E Dezern, Marie Sebert, Guillermo Garcia-Manero

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case of G12C-Mutated AML Treated With Sotorasib.
Dimitrios Drekolias, Todd C Knepper, Quan Lovette, David A Sallman

JCO Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes.
Matteo Zampini, Elena Riva, Luca Lanino, Elisabetta Sauta, Rita Antunes Dos Reis, David Sallman

J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm.
Zhuoer Xie, Najla Al Ali, Ling Zhang, Peter Papenhausen, Virginia Olivia Volpe, David A Sallman

Blood Neoplasia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
Peter L Greenberg, Richard M Stone, Yasmin Abaza, Aref Al-Kali, Sarah Anand, David A Sallman

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, David A Sallman

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia.
Ellen Madarang, Jillian Lykon, Wei Zhao, Mikkael A Sekeres, Terrence Bradley, David A Sallman

Blood Neoplasia· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis